In this webinar, Caroline Bullerjahn, Tucker DeVoe, and Justin Ward from Goodwin, and Frank Schneider from Cornerstone Research will discuss key updates and recent trends concerning securities class actions filed against publicly traded pharmaceutical, biotechnology, medical device and healthcare product and services companies (collectively, “life sciences companies”), which continue to…
Publicly traded life sciences companies continue to be the primary target of the plaintiffs’ bar, facing far more securities class action lawsuits compared to other sectors. What does this mean for your business, and what practical steps can you take to make informed choices? Join Caroline Bullerjahn, Courtney Orazio, and…
Despite the turmoil and disruption of 2020, plaintiffs’ lawyers and courts appear to have adapted readily to our “new normal.” Although at lower rates than previous years, plaintiffs’ firms continued to file securities class actions against publicly traded pharmaceutical, biotechnology, medical device and healthcare product and services companies in 2020,…
